These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 2512686

  • 1. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
    Schneider J, Friderichs E, Günzler WA, Flohé L.
    Thromb Res; 1989 Oct 01; 56(1):59-65. PubMed ID: 2512686
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D, Stassen JM, De Cock F.
    Thromb Haemost; 1987 Oct 28; 58(3):943-6. PubMed ID: 3124288
    [Abstract] [Full Text] [Related]

  • 3. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR, Lijnen HR, Stassen JM, Collen D.
    Blood; 1991 Jul 01; 78(1):125-31. PubMed ID: 1906351
    [Abstract] [Full Text] [Related]

  • 4. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 01; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 6. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 7. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF, Voytik S, Klabunde RE, Henkin J, Leski M.
    Thromb Res; 1988 Nov 15; 52(4):295-312. PubMed ID: 3144052
    [Abstract] [Full Text] [Related]

  • 8. Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi.
    Schneider J.
    Prostaglandins; 1991 Jun 15; 41(6):595-606. PubMed ID: 2052741
    [Abstract] [Full Text] [Related]

  • 9. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 10. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB, Moukhametova LI, Varfolomeyev SD.
    Biochemistry (Mosc); 2003 Nov 02; 68(11):1252-60. PubMed ID: 14640969
    [Abstract] [Full Text] [Related]

  • 11. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb 02; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 12. Synergism of thrombolytic agents in vivo.
    Collen D, Stassen JM, Stump DC, Verstraete M.
    Circulation; 1986 Oct 02; 74(4):838-42. PubMed ID: 3093116
    [Abstract] [Full Text] [Related]

  • 13. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
    Spriggs DJ, Stassen JM, Hashimoto Y, Collen D.
    Blood; 1989 Apr 02; 73(5):1207-12. PubMed ID: 2495034
    [Abstract] [Full Text] [Related]

  • 14. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May 02; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

  • 15. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
    Stump DC, Stassen JM, Demarsin E, Collen D.
    Blood; 1987 Feb 02; 69(2):592-6. PubMed ID: 3099862
    [Abstract] [Full Text] [Related]

  • 16. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D.
    Thromb Haemost; 1987 Oct 28; 58(3):947-50. PubMed ID: 2829381
    [Abstract] [Full Text] [Related]

  • 17. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D.
    Blood; 1991 Aug 15; 78(4):1005-18. PubMed ID: 1831057
    [Abstract] [Full Text] [Related]

  • 18. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET, Mack DL, Sobel BE.
    Thromb Haemost; 1989 Nov 24; 62(3):909-16. PubMed ID: 2512679
    [Abstract] [Full Text] [Related]

  • 19. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D.
    Prog Hemost Thromb; 1986 Nov 24; 8():1-18. PubMed ID: 3104986
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988 Nov 24; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.